Marc Carrier/LinkedIn;Caterina E. Marx
/researchgate.net
Apr 17, 2026, 12:44
Marc Carrier: A Practical Approach to Recurrent Thrombosis in Cancer Patients
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Managing recurrent VTE despite anticoagulation in patients with cancer remains one of the most challenging scenarios in thrombosis care.
This ‘How I Treat’ review outlines a pragmatic potential approach:
- Confirm true recurrence (versus residual clot)
- Assess adherence, drug interactions, and absorption
- Optimize anticoagulation (LMWH escalation or switch)
Despite these strategies, recurrence and bleeding risks remain substantial highlighting the urgent need for more high-quality data.”
Title: How I treat breakthrough thrombosis in patients with cancer
Authors: Caterina E. Marx, Marc Carrier
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 5, 2026, 16:28Jon Douglas: Imperial College London Review Maps Key Pathways in Autoimmune Thrombosis
-
Sep 5, 2026, 16:21Kelly Anderson: Bilateral Foot Pain and Purple Toes – Spotting Vascular Complications in Polycythemia Vera
-
Sep 5, 2026, 16:16Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis
-
Sep 5, 2026, 16:08Indre Ceponiene: Major Gaps in Secondary Cardiovascular Prevention Across Europe
-
Sep 5, 2026, 16:03W. Alberto Sifuentes Giraldo: Why Obstetric Cases Are Missed Under 2023 ACR/EULAR APS Criteria
-
Sep 5, 2026, 15:58Srikanth Nalla: A Case of Saddle Pulmonary Embolism
-
Sep 5, 2026, 15:55COPD-specific Pulmonary Embolism Diagnostic Strategy – Thrombosis and Haemostasis
-
Sep 5, 2026, 15:41Sam Tsimikas on Lp(a) HORIZON Topline Results – What Missed Endpoints Mean for Cardiovascular Risk
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?